Ventrus Biosciences, Inc. (Ventrus) is a specialty pharmaceutical company focused on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. Its product candidate portfolio consists of three late-stage drugs intended to treat these conditions: one new chemical entity (NCE) and two previously approved molecules that will have market exclusivity for new and patentable topical gastrointestinal indications. The Company�s three late-stage product candidates are Iferanserin ointment (VEN 309) for the treatment of hemorrhoids, Diltiazem cream (VEN 307), a treatment for the relief of pain associated with anal fissures and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis (IPAA). On November 14, 2011, the Company acquired Sam Amer & Co.